MOTS-c Mechanism of Action

Introduction

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene (MT-RNR1), first characterized by Lee and colleagues in 2015 [1]. Published research has described two interconnected functional modes: a cytoplasmic metabolic signaling pathway centered on AMPK activation, and a nuclear translocation pathway through which the peptide participates in adaptive gene regulation under stress. The mechanistic literature on MOTS-c is an active and growing field; findings described below reflect published studies from cell culture and rodent models unless otherwise indicated. Background on the peptide's structure and classification is available in the MOTS-c research overview.

Receptor Target and Primary Signaling Pathway

The 2015 discovery paper by Lee et al. reported that MOTS-c, upon cellular uptake, inhibits the folate cycle—specifically at the step involving 5-methyl-tetrahydrofolate (5-Me-THF), which is tightly coupled to the de novo purine biosynthesis pathway [1]. This inhibition was reported to produce a greater-than-20-fold accumulation of endogenous AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a well-characterized direct agonist of AMP-activated protein kinase (AMPK), in MOTS-c-treated human embryonic kidney (HEK293) cells compared with controls [1].

AMPK is a hetero-trimeric serine/threonine kinase serving as a central cellular energy sensor, activated when intracellular AMP:ATP ratios rise. The reported AICAR-driven AMPK activation downstream of MOTS-c's folate cycle inhibition was observed in both cell culture and in mouse skeletal muscle following peripheral administration of the peptide [1]. This indirect AMPK activation through an endogenous metabolite intermediate distinguishes MOTS-c from direct AMPK agonists and has drawn continued research interest.

Reported Molecular Interactions

A 2019 study published in Physiological Reports by Kim, Miller, Mehta, and colleagues used targeted metabolomics in mice administered MOTS-c to characterize the downstream metabolic profile [2]. The authors reported alterations in sphingolipid, monoacylglycerol, and dicarboxylate metabolic pathways in MOTS-c-treated animals relative to controls. These pathways had previously been associated with insulin-resistant states in published literature, and the authors noted their reduction in treated animals while acknowledging that causality between the metabolomic shifts and any specific outcome remained to be established in future work.

In 2024, Lee and colleagues published in iScience a study identifying casein kinase 2 (CK2) as a direct binding partner and functional target of MOTS-c in skeletal muscle [4]. The authors reported that MOTS-c bound directly to CK2 in cell-free systems, and that systemic MOTS-c administration in mice was associated with differential CK2 activity in muscle versus adipose tissue—activation in muscle and suppression in fat—mediated by distinct CK2-interacting protein partners at each tissue site [4]. A naturally occurring human MOTS-c sequence variant, K14Q MOTS-c, exhibited reduced CK2 binding; male carriers of this variant showed a statistically higher association with sarcopenia and type 2 diabetes in an age- and physical-activity-dependent manner in observational data [4]. The authors characterized this as preliminary genetic evidence linking endogenous MOTS-c-CK2 signaling to musculoskeletal metabolic phenotypes in humans.

Nuclear Translocation and Gene Regulation

A distinct and particularly notable mechanism was described by Kim, Son, Benayoun, and Lee in a 2018 Cell Metabolism paper [3]. The authors reported that MOTS-c can translocate from the cytoplasm to the nucleus within approximately 30 minutes of metabolic stress—induced experimentally by glucose restriction, serum deprivation, or oxidative stress in cultured cells. This translocation was reported to be dependent on AMPK activity, as pharmacological AMPK inhibition attenuated nuclear accumulation of MOTS-c [3].

In the nucleus, MOTS-c was reported to regulate a broad set of genes in response to glucose restriction, including genes carrying antioxidant response elements (AREs) in their promoters. The authors described interactions between MOTS-c and ARE-regulating transcription factors including NRF2 (nuclear factor erythroid 2-related factor 2), and framed this nuclear activity as a form of mitochondrial-to-nuclear retrograde signaling—a mechanism by which the mitochondrial genome communicates directly with the nucleus under conditions of metabolic or oxidative stress [3]. This discovery attracted substantial attention from researchers studying organellar communication.

Downstream Effects Reported in Research Models

The 2015 Lee et al. publication reported that MOTS-c administration in high-fat-diet-fed and genetically obese (ob/ob) mouse models was associated with altered glucose tolerance test profiles, changes in adiposity measures, and insulin tolerance test outcomes compared with vehicle-treated controls [1]. These findings were attributed to AMPK activation in skeletal muscle and attendant effects on glucose transporter expression and lipid oxidation pathways. The authors characterized these as preclinical findings requiring further investigation before implications for human biology could be assessed.

Reynolds and colleagues, in a 2021 Nature Communications paper, reported that exercise in young male human subjects (n=10) was associated with an approximately 11.9-fold rise in intramuscular MOTS-c expression and an approximately 1.6-fold rise in circulating plasma levels [5]. The human component was observational and limited in sample size; the authors described the findings as consistent with a role for endogenous MOTS-c in physiological adaptation to exercise.

A 2024 study published in Antioxidants by Zhang, Huang, and colleagues examined MOTS-c in a rodent radiation pneumonitis model and reported that MOTS-c administration was associated with reduced lung tissue inflammatory markers and oxidative stress in a manner dependent on NRF2 pathway activity, as assessed by pathway inhibitor experiments [6]. All observations were in animal or cell models. Research on MOTS-c from SpartaLabs is supplied as verified research-grade material for laboratory use.

Findings from research models do not establish safety or efficacy in humans. SpartaLabs makes no claims about the use of this compound.

Areas of Active Investigation

The mechanistic characterization of MOTS-c is an evolving field with several areas where research is ongoing. The specific cell-surface receptor mediating MOTS-c uptake into target cells—if such a receptor exists—has not yet been conclusively identified, and its determination would substantially advance understanding of tissue selectivity. The relative contribution of the folate-AICAR-AMPK axis, the CK2 axis, and the nuclear translocation pathway in specific physiological or pathological contexts is an area of active inquiry. Published pharmacokinetic characterization of exogenously administered MOTS-c in humans—including absorption, distribution, metabolism, and elimination—represents a logical next step in translational research.

The physiological significance of age-related changes in circulating MOTS-c levels observed in human cohorts, and how endogenous signaling may differ from exogenous administration, are themes that current review literature identifies as the most productive avenues for future investigation, as discussed in the 2023 Wan et al. review in the Journal of Translational Medicine [7]. For a comparable perspective on another mitochondrially targeted peptide operating in the oxidative stress axis, the SS-31 mechanism of action provides a useful point of comparison within the same research cluster.

References

1. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015 Mar 3;21(3):443–454. doi: 10.1016/j.cmet.2015.02.009. PMID: 25738459. https://pubmed.ncbi.nlm.nih.gov/25738459/

2. Kim SJ, Miller B, Mehta HH, Xiao J, Wan J, Arpawong TE, Yen K, Cohen P. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep. 2019 Jul;7(13):e14171. doi: 10.14814/phy2.14171. PMID: 31318170. https://pubmed.ncbi.nlm.nih.gov/31318170/

3. Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018 Sep 4;28(3):516–524.e7. doi: 10.1016/j.cmet.2018.06.015. PMID: 29983246. https://pubmed.ncbi.nlm.nih.gov/29983246/

4. Zhu Z, Qian M, Joly JH, Lu R, Mehta HH, Cohen P, Lee C. MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience. 2024 Oct 19;27(11):111215. doi: 10.1016/j.isci.2024.111215. PMID: 39559755. https://pubmed.ncbi.nlm.nih.gov/39559755/

5. Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021 Jan 20;12(1):470. doi: 10.1038/s41467-020-20790-0. PMID: 33473109. https://pubmed.ncbi.nlm.nih.gov/33473109/

6. Zhang Y, Huang J, Zhang Y, Jiang F, Li S, He S, Sun J, Chen D, Tong Y, Pang Q, Wu Y. The mitochondrial-derived peptide MOTS-c alleviates radiation pneumonitis via an Nrf2-dependent mechanism. Antioxidants (Basel). 2024 May 17;13(5):613. doi: 10.3390/antiox13050613. PMID: 38790718. https://pubmed.ncbi.nlm.nih.gov/38790718/

7. Wan W, Zhang L, Lin Y, Rao X, Wang X, Hua F, Ying J. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. J Transl Med. 2023 Jan 20;21(1):36. doi: 10.1186/s12967-023-03885-2. PMID: 36670507. https://pubmed.ncbi.nlm.nih.gov/36670507/